• Reuters

  • SHARE

Takeda Pharmaceutical Co. said it would contest $6 billion in punitive damages imposed by a jury in the United States in a case that accused Japan’s largest drugmaker of concealing cancer risks associated with its Actos diabetes drug.

Eli Lilly and Co., Takeda’s co-defendant in the case, was ordered to pay $3 billion in punitive damages by the jury in Louisiana on Monday. It also awarded $1.48 million in compensatory damages.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW